Work

Expression Profiling of Ovarian Cancer: markers and targets for therapy

Year: 2006
Type: dissertation
Study design: Observational Study
Abstract: Ovarian cancer is the leading cause of death from gynecological cancer in the Western world. The initial response\\nof the primary tumor to taxane and platinum-based chemotherapy is high, however 20% of patients never achieve\\na clinical response and the majority of the patients will relapse and eventually die of drug-resistant disease.\\nChapter 1 includes a general overview of ovarian cancer, its epidemiology, histology, typing and the different\\ntherapies. The major drawback in the treatment of ovarian cancer is late detection and therapy failure due to\\nintrinsic and acquired chemotherapy resistance and several mechanisms involved in the platinum-based\\nchemotherapy resistance are described. Furthermore, the importance of expression profiling (mRNA or protein)\\nin the search for tumor markers suitable for early detection of ovarian cancer, response prediction, progression\\nmonitoring and identification of targets for therapy is discussed.\\nChapter 2A The expression profiling of 24 ovarian carcinomas led to the discovery of a discriminating 69-gene\\nsignature from which a predictive nine-gene set was extracted. The nine-gene set predicted the resistance in\\nan independent validation set (n=72) with a sensitivity of 89% (95% CI: 0.68-1.09) and a specificity of 59% (95%\\nCI: 0.47-0.71)(OR=0.09, p=0.026). The predictive nine-gene set consists of the following genes, FN1, TOP2A, LBR,\\nASS, COL3A1, STK6, SGPP1, ITGAE and PCNA. Interestingly, three of these nine genes are already direct or indirect\\ntargets for therapy, i.e. topoisomerase 2A (TOP2A), serine/threonine kinase 6 (STK6) and argininosuccinate\\nsynthetase (ASS). The predictive power of the nine-gene set needs to be further validated in larger independent\\nmulticenter study before this model can be implemented in the clinical practice.\\nChapter 2B In their \\xc3\\xa2?~letter to the editor\\xc3\\xa2?T, Gevaert et al. suggest that in clinical practice, a higher specificity would\\nhave been more successful assuming that patients predicted not to respond are given a different treatment\\nnot containing platinum drugs. We agree that the predictive gene signature needs further validation before\\nimplementation in the clinical practice can be advised. However, it is was not our intention to withhold platinum\\ntreatment from patients predicted not to respond, but to tailor the treatment based on the expression profile.\\nAn overexpression of TOP2A indicates that adding a TOP2A inhibitor, like etoposide, to the conventional platinum\\ntreatment, might proof to be beneficial for the patient.\\nChapter 2C Underexpression of one of the nine genes from the predictive gene set, i.e. Argininosuccinate\\nsynthetase (ASS) was associated with platinum-based chemotherapy resistance. To determine if this observed\\nassociation was functional, ASS was downregulated with siRNA in three ovarian cancer cell lines that were relatively\\nsensitive to cisplatin. For all three cell lines, this did not result in a reduced response to cisplatin measured with\\nan MTT assay. However, due to differences between cell lines and carcinomas, we cannot exclude that ASS\\nmight still play a role in platinum-based chemotherapy resistance in ovarian cancer patients.\\nChapter 3 One of the nine genes of the predictive gene set i.e. proliferating cell nuclear antigen (PCNA), is involved\\nin the DNA mismatch repair (MMR). In vitro, a relationship between MMR deficiency and platinum-drug resistance\\nwas suggested. However, no microsatellite instability (which is a marker for MMR deficiency) was detected in 75\\nprimary ovarian carcinomas of which 46 received platinum-based chemotherapy. Thus resistance seen in 11\\npatients was not associated with an deficient MMR. An overview of published data revealed an overall frequency\\nof MMR inactivation of 13% (165/1315, range: 0-39%). Interestingly, this was higher in mucinous and endometrioid\\nwhen compared to clear cell and serous ovarian carcinomas.\\nChapter 4 Gene expression profiling studies leading to prediction of treatment resistance in breast and ovarian\\ncancer, show only a few overlapping genes. This could be explained by heterogeneity of the disease, patient\\npopulations studied, different platforms and approach of statistical analysis. Moreover, overlapping pathways\\nmay be present but overlooked since each gene signature could contain different genes from the same pathway.\\nOne gene, fibronectin (FN1), is overlapping in our two profiling studies in breast and ovarian cancer. FN1 is involved\\nin cell adhesion mediated drug resistance (CAM-DR) and down regulation was associated with paclitaxel resistance\\nin breast and ovarian epithelial cancer cell lines. Therefore, FN1 and its relation with the response to different\\ntherapeutics might be interesting for future investigations.\\nChapter 5 Little overlap was seen between seven published gene signatures associated with platinum-based\\nchemotherapy response in ovarian cancer. Therefore, pathway analysis was done to determine if there are\\ncommon pathways. Gene Ontology analysis revealed six functional processes that were represented in all\\nseven gene signatures. Each process was further analyzed in Ingenuity Pathway Analisys and remarkably TNF,\\nP53 and TGFB were identified as common key genes. In the future, besides using the identified signatures for\\nprediction, pathway analysis could lead to a better insight in the functional relationship between specific\\npathways and ovarian cancer and chemotherapy resistance. This could lead to a more educated selection of\\ntargets for therapy.\\nChapter 6 SELDI-TOF MS was used to discover ovarian cancer biomarkers by comparing serum protein profiles\\nof ovarian cancer patients at diagnosis (n=35) or at progression (n=43), with that of healthy individuals (n=31).\\nThis resulted in eight primary and eleven progression ovarian cancer biomarkers, with four overlapping\\nbiomarkers. In addition, we compared the sera profiles from ovarian cancer patients after platinum-based\\nchemotherapy (n=12) with that of ovarian cancer patients at progression (n=24) and discovered ten potential\\nprogression monitoring markers of which one was identified as serum amyloid A1 and validated with ELISA.\\nFurther validation would reveal the use of these biomarkers in screening and monitoring progression of ovarian\\ncancer.\\nChapter 7 The generation and characterization of an A2780 mutant ovarian cancer cell line that is resistant to\\nand shows a reduced accumulation of cisplatin, carboplatin, oxaliplatin and tetraplatin but not transplatin. This\\nimpaired accumulation could not be attributed to the known cisplatin transporters MRP2, CTR1, ATP7A or\\nATP7B and the platinum efflux rate was similar to that of A2780. The resistance could be overcome by circumvention\\nof the natural influx mechanisms with cisplatin nanocapsules (nanoprecipitates of cisplatin coated with a lipid\\nbilayer), indicating a defect in influx mechanism. The striking specificity of this influx mechanism to platinum\\ncompounds in the cis-configuration suggests that not passive diffusion but a platinum specific transporter is\\ninvolved in the impaired platinum influx and resistance in A2780-Pt.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W2135735026
Cites: 215
Cited by: 1
Related to: 10